MOLECULAR DIAGNOSTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as -

Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Cepheid
CytoCore Inc.


Click here to request a full list of companies covered in the report...

Code : MCP-1226
Price : $4950
Companies : 165
Pages : 616
Date : July 2014
Market Data Tables : 118
Status: * New Report

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Molecular Diagnostics – A Prelude.....II-11$100
   Current and Future Analysis.....II-21$100
   US and Europe – Leaders in Molecular Diagnostics Adoption.....II-3
Developing Countries Excel in Growth Prospects.....II-3
2$200
   Major Growth Drivers.....II-5
Key Market Trends in a Nutshell.....II-5
1$100
   Major Technology Trends.....II-6
Major Issues and Challenges.....II-6
The Future in Store.....II-6
2$200
   Clinical Diagnostics Industry – Trends and Tendencies.....II-81$100
   Global In-Vitro Diagnostics (IVD) Market: A Prelude.....II-9 1$100
   Table 1: Global In Vitro Diagnostics Market by Leading Players (2013): Percentage Share Breakdown of Revenues for Abbott Laboratories, bioMérieux, Danaher, J&J, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart).....II-10

Table 2: Global In-Vitro Diagnostics Market by Segment (2013): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart).....II-10
1$350
   Table 3: Global In-Vitro Diagnostics Market by Sector (2013): Percentage Breakdown of Revenues for Decentralized & Patient Self-Testing and Hospital & Commercial Laboratories (includes corresponding Graph/Chart).....II-11
Classification of Diagnostic Tests.....II-11
Molecular Diagnostics – A Replacement and Enabling Technology.....II-11
1$350
   Advancements in Molecular Diagnostics - A Boon for the Industry.....II-12
Nucleic Acid Diagnostics Market – An Overview.....II-12
2$200
   Molecular Diagnostics – A Rapidly Advancing Market.....II-141$100
   Molecular Diagnostics: Marking the Convergence of Numerous Technologies.....II-15
Towards Tailoring the Right Treatment for the Right Disease.....II-15
Business Opportunities in the Offing.....II-15
1$100
   Improving Healthcare Expenditure Turbo Charges Demand.....II-16
Table 4: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart).....II-16
1$350
   Table 5: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart).....II-171$350
   Table 6: Top 10 Countries with Highest Private Spending on Health Care (2011) (includes corresponding Graph/Chart).....II-18
Demographics Spell Growth Opportunities.....II-18
1$350
   Table 7: Global Population Statistics for the 65+ Age Group (2013) (includes corresponding Graph/Chart).....II-191$350
   Table 8: Elderly Population (60+ Years) as a Percentage of the Total Population (2012 & 2050) (includes corresponding Graph/Chart).....II-201$350
   Table 9: Global Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....II-211$350
   Table 10: Aging Population by Age Group in More Developed Countries (1975-2050) (includes corresponding Graph/Chart).....II-221$350
   Table 11: Aging Population by Age Group in Less Developed Countries (1975-2050) (includes corresponding Graph/Chart).....II-231$350
   Table 12: Aging Population by Age Group in Least Developed Countries (1975-2050) (includes corresponding Graph/Chart).....II-241$350
   Table 13: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart).....II-25
Technological Innovations Set to Drive the Market.....II-25
2$350
   The Role of Molecular Diagnostics in Personalized Medicine.....II-271$100
   Companion Diagnostics Make Way for Personalized Medicine.....II-28
List of Select FDA-Cleared Companion Diagnostic Devices.....II-28
1$100
   Biomarkers as Companion Diagnostics.....II-291$100
   Proteomics Technologies: Growing in Significance.....II-301$100
   New Developments in Proteomics Technologies.....II-31
New Applications Hold Promising Potential.....II-31
1$100
   Molecular Diagnostics for Lymphoid Malignancies.....II-321$100
   Next-Generation Sequencing Technologies Keep Up the Momentum.....II-33
Select Commercial NGS Technologies.....II-33
1$100
   Select Promising NGS Technologies in Development (As of 2012).....II-34
Rising Emphasis on Lab Automation to Augur Well for Market Growth.....II-34
1$100
   List of Fully Automated and Rapid Molecular Diagnostics.....II-35
Molecular Diagnostics and Intellectual Property.....II-35
1$100
   Medical Training and Practice Challenges.....II-36
The Enlightened Consumer of the 21st Century.....II-36
Information Handling & Processing: The Soft Side of Diagnostics.....II-36
Hurdles All the Way for Companies Eyeing Molecular Diagnostics.....II-36
1$100
   Molecular Diagnostics – Moving from Centralization to Decentralization.....II-37
Migrating to Decentralized Format.....II-37
1$100
   Going Ahead with Decentralization.....II-38
Limited Reimbursements by Third Party Payers – A Stumbling Block.....II-38
1$100
   Infectious Diseases Molecular Testing.....II-39
Overview.....II-39
Activity in the Field.....II-39
1$100
   Identifying Multidrug Resistance.....II-40
Infectious Disease Treatment Monitoring.....II-40
Other Infectious Diseases Applications.....II-40
Key Trends.....II-40
Increasing Incidence of Infectious Diseases Fuel Adoption.....II-40
1$100
   Table 14: Reported Cases of Major Infections by Select Geographic Region: 2011.....II-41
Rising Incidence of Hospital Acquired Infections Propels Market Growth.....II-41
2$700
   Comparison of Different Parameters for Select C. diff MDx Tests.....II-43
Rising HIV Prevalence Provides Ample Growth Opportunities.....II-43
1$100
   Table 15: Global Prevalence of HIV Infection in 2012 by Region (in Millions) (includes corresponding Graph/Chart).....II-44

Table 16: Newly Infected HIV Population in 2012 by Region (in Millions) (includes corresponding Graph/Chart).....II-44
1$350
   Table 17: Global HIV Related Deaths in 2012 by Region (in Millions) (includes corresponding Graph/Chart).....II-45

Table 18: Top Twelve Countries in APAC with The Highest HIV Incidence (2012) (includes corresponding Graph/Chart).....II-45
1$350
   Infectious Disease Testing – A Major Driver of Molecular Diagnostics Market.....II-461$100
   Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases.....II-474$400
   Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market.....II-511$100
   Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing.....II-521$100
   HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing
  Market.....II-53
1$100
   List of Select HPV Molecular Diagnostic Tests by Company and Technique.....II-54
Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular
  Diagnostics.....II-54
2$200
   List of Select Commercially-Available TB Diagnostics.....II-56
An Overview of Select TB Diagnostics under Development.....II-56
1$100
   Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential
  .....II-57
PCR Plays a Vital Role in the Diagnosis of Infectious Diseases.....II-57
1$100
   Blood Screening.....II-58
Molecular based Tests Ingrain Roots in Blood Donor Screening Segment.....II-58
1$100
   Cancer Screening & Diagnosis.....II-59
Overview.....II-59
1$100
   Molecular Tests Lead the Way for Cancer IVD Market Growth.....II-60
Molecular Markers to Enhance Thyroid Cancer Diagnosis.....II-60
1$100
   Oncology-Based Molecular Diagnostics: The Propitious Segment.....II-612$200
   List of US-FDA Approved Biomarkers for Cancer.....II-63 1$350
   Table 19: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart).....II-64

Table 20: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart).....II-64
1$350
   Table 21: Medical Costs Associated with Cancer by Affected Site: 2010 (includes corresponding Graph/Chart).....II-65
Growing Popularity of Chemo-Sensitivity Testing of CTCs.....II-65
1$350
   Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers.....II-66
Other Testing Applications.....II-66
Genetic Disease Testing Applications.....II-66
Overview.....II-66
1$100
   Pharmacogenomics – Prognosis Based on Genomics.....II-671$100
   Pharmacogenomics Development Augurs Growth of Genetic Testing Market.....II-68
Prospects for Genetic Diagnostics and Testing Grow Brighter.....II-68
2$200
   List of Select FDA-Cleared Genetic Tests by Disease.....II-701$100
   Genetic Testing – An Indispensible Tool for Cystic Fibrosis.....II-71 1$350
   Table 22: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart).....II-72
Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions.....II-72
1$350
   Non-Invasive Prenatal Diagnostics – The Way Ahead.....II-73
Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance.....II-73
PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents.....II-73
1$100
   Histocompatibility Testing.....II-74
Table 23: Global HLA Testing Market (2012-2016E): Revenue Estimates for 2012 through 2016 (includes corresponding Graph/Chart).....II-74
1$350
   Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market.....II-75
An Overview of Competitive Landscape in Molecular Diagnostics.....II-75
1$100
   Table 24: Leading Players in the Global Molecular Diagnostics Market (2012): Percentage Share Breakdown by Value Sales for Abbott, Becton, Dickinson & Company, bioMérieux, Cepheid, Hologic/Gen-Probe, Novartis, Qiagen, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart).....II-76
Other Noteworthy Companies and their Competitive Position by Segment.....II-76
1$350
   Key Players and Their Technologies.....II-77
The Top Tier.....II-77
Mid-Sized and Small Companies.....II-77
1$100
   Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market.....II-781$100
   Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics.....II-79
Qiagen: The Leading Player in the Global HPV MDx Market.....II-79
Comparative Analysis of Select HPV MDx Tests.....II-79
1$100
   Competitive Dynamics in the C. difficile Testing Market.....II-80
Table 25: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian and Others (includes corresponding Graph/Chart).....II-80
List of Select Molecular C. difficile Test Products.....II-80
Competition in the Blood Screening MDx Market.....II-80
1$350
   Table 26: Global Blood Screening MDx Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for Hologic Gen-Probe, Roche and Others (includes corresponding Graph/Chart).....II-81
Competitive Landscape in the Global RT-PCR Market.....II-81
1$350
   Table 27: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Life Technologies, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart).....II-82
Select Real-Time PCR Products by Company.....II-82
Competition Heats Up in dPCR Market.....II-82
1$350
   Table 28: Leading dPCR Systems At a Glance.....II-83
Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market.....II-83
1$350
   Consolidation Activity Continues to Strengthen Driven by New Entrants.....II-841$100
   Major M&A Transactions in Molecular Diagnostics: 2011-2014.....II-851$100
   New Entrants in Molecular Diagnostics Landscape: 2010-2013.....II-861$100
   Some Examples of Recent Transactions by New Entrants in the MDx Market.....II-87
Product Marketing – Key to Commercial Success.....II-87
1$100
   Molecular Diagnostics – Definition & Scope.....II-88
Molecular Diagnostics – Impact on Healthcare.....II-88
1$100
   Utility of Molecular Diagnostic Tests.....II-89
Background of Molecular Diagnostics.....II-89
Major Milestones in the Evolution of Molecular Diagnostics.....II-89
1$100
   Types of Molecular Diagnostics.....II-901$100
   Conventional Diagnostics Vs. Molecular Diagnostics.....II-91
Unabated Developments in Molecular Diagnostics Technology.....II-91
Signal Amplification Technologies.....II-91
PCR – New Developments.....II-91
1$100
   Quantitative Real-Time PCR for Molecular Diagnostics.....II-921$100
   Signal Detection and Quantification.....II-93
Quantitative Real-Time RT-PCR Analysis.....II-93
Applications of Quantitative Real-Time PCR Analysis.....II-93
1$100
   Digital PCR.....II-94
Non-PCR Methods.....II-94
Other Signal Amplification Technologies.....II-94
DNA Probe Based Products.....II-94
Direct Detection of Specific Nucleic Acid Sequences.....II-94
1$100
   Nucleic Acid Amplification and Detection.....II-95
DNA Sequencing and Gene Detection.....II-95
1$100
   Arrays of Immobilized Probes (DNA Chips) in Gene Detection.....II-96
RNA Diagnostics.....II-96
1$100
   Complementary Molecular Diagnostic Technologies.....II-97
Fluorescent In-Situ Hybridization (FISH).....II-97
DNA Biochips/Microarrays.....II-97
1$100
   Biosensors.....II-98
Proteomic Technologies for Molecular Diagnostics.....II-98
1$100
   Nanotechnology for Molecular Diagnostics.....II-99
Technologies on the Anvil.....II-99
Haplotype Analysis – A Distant Possibility.....II-99
1$100
   Chronic Multi-Gene Defects Now Diagnosable.....II-100
Whole Genome Sequencing – Boon or Bane to Genetic Testing?.....II-100
1$100
   Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit.....II-101
QIAGEN Rolls Out careHPV™ Test in India.....II-101
QIAGEN Gets PMA Approval from the US FDA for artus® CMV RGQ MDx Kit.....II-101
Alere Obtains FDA Approval for Alere™ i Influenza A and B Test.....II-101
Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit.....II-101
Immucor Obtains the US FDA Approval for PreciseType HEA Test.....II-101
1$100
   bioMérieux Obtains PMA Approval from the FDA for THxID™-BRAF Companion Diagnostic
  Test.....II-102
Cepheid Obtains FDA Clearance for Xpert® MTB/RIF Test.....II-102
Roche Gains FDA 510(k) Approval to use Four Additional Specimens with Cobas Ct/Ng
  V2.0 Test.....II-102
PrimeraDx Gains FDA 510(k) Clearance for ICEPlex System.....II-102
Illumina Receives FDA Premarket Approval for Miseqdx System.....II-102
1$100
   Hologic Obtains Health Canada Approval for Aptima HPV Assay.....II-103
Life Technologies Obtains NDIS Approval for GlobalFiler Express Kit.....II-103
Serascience Obtains CE Mark Approval for Seralite®.....II-103
IntelligentMDx Obtains US FDA Approval for Automated Molecular Diagnostic
  Test.....II-103
Meridian Bioscience Obtains FDA Approval for illumigene® Mycoplasma.....II-103
IntelligentMDx Obtains CE-Mark Approval for IMDx Flu A/B and RSV Test.....II-103
1$100
   BD Diagnostics Obtains FDA Approval for BD MAX™ Cdiff Assay.....II-104
Quidel Obtains 510(k) Approval for Quidel Molecular RSV + hMPV Assay.....II-104
Roche Seeks FDA Approval for Cervical Cancer Primary Screening Indication for the
  Cobas® Hpv Test.....II-104
Quidel Gets FDA Nod for New Molecular Diagnostic Tests.....II-104
Abbott Launches RealTime Molecular Test for HPV.....II-104
Diagnovus Introduces ENGAUGE™-Cancer DLBCL Gene Panel.....II-104
1$100
   Roche Introduces Cobas p 480 Instrument.....II-105
LabCorp Launches BRCAssureSM Breast Cancer Mutation Tests.....II-105
Cytocell Introduces Cytocell CLL FISH Probes.....II-105
Cancer Genetics Introduces FHACT™ DNA-Based Cervical Cancer Diagnostic Test.....II-105
Abbott Releases IMDx C.difficile Test.....II-105
Myriad Genetics Introduces myPath™ Melanoma Molecular Diagnostic Test.....II-105
1$100
   Biocartis Develops New MDx Prototype Platform.....II-106
BioChain Collaborates with Epigenomics to Introduce Septin9 IVD Test.....II-106
Advanced Cell Diagnostics and Kindstar Partner to Introduce New Molecular Diagnostic
  Assays.....II-106
EKF Diagnostics Introduces Four New PointMan™ DNA Enrichment Kits.....II-106
DiaCarta Introduces QClamp™ Somatic Mutation Real-Time PCR Tests.....II-106
Biocartis to Launch Idylla Molecular Diagnostic Platform.....II-106
Personalis Launches the ACE Clinical Exome™.....II-106
1$100
   Roche to Launch Cobas 6800 and Cobas 8800 MOLECULAR Dx Systems.....II-107
Illumina Launches TruSight One Sequencing Panel .....II-107
Abbott Laboratories Releases New FDA-Approved Molecular Diagnostic Flu A/B and RSV
  Test.....II-107
Natural Molecular Testing Releases New Diagnostic Molecular Tests for Women.....II-107
DiaSorin’s Molecular Division Launches Iam Toxo Assay for T. gondii Detection.....II-107
Myriad Genetics Introduces myRisk™ Hereditary Cancer Panel.....II-107
1$100
   BD Diagnostics Launches FDA-Cleared BD ProbeTec™ Trichomonas Vaginalis Qx Amplified
  DNA Assay.....II-108
ELITechGroup Molecular Diagnostics Introduces ELITe STAR.....II-108
Assurex Health Launches GeneSight Psychotropic 2.0.....II-108
Theradiag Rolls Out two new Multiplexed Molecular Diagnostic Assays.....II-108
Bioline Releases the MyTaq™ Extract-PCR Kit.....II-108
HTG Rolls Out HTG Edge DMPK Assay and HTG Edge TOA Assay.....II-108
1$100
   BD Diagnostics Introduces Real-Time PCR Kit for Diagenode Bordetella
  Pertussis/Parapertussis Detection.....II-109
Abbott Launches Real-time HCV Genotype II Test.....II-109
Abbott Introduces FDA-Approved Real-Time HCV Genotyping Test Assay.....II-109
DiaSorin Releases New IAM PARVO Molecular Diagnostic Test for Parvo Virus
  Detection.....II-109
GeneDx to Introduce Comprehensive Breast Cancer Genetic Tests.....II-109
1$100
   Vela Diagnostics Develops New PCR-based Assays Targeting the H7N9 Bird Flu
  Strain.....II-110
Cancer Genetics Introduces UroGenRA™ Urogenital Cancer Array.....II-110
Bioline Releases ISOLATE II Nucleic Acid Purification Kits.....II-110
MLabs Announces Commercial Availability of MiPS Test for Prostate Cancer.....II-110
Cancer Genetics Introduces New Genetic Test for Cervical Cancer Management.....II-110
Knight Diagnostic Laboratories Launches GeneTrails Cancer Tests.....II-110
1$100
   Integrated Diagnostics Releases Xpresys™ Lung Blood Test.....II-111
Seegene Unveils Real-Time Array Technology for POC Testing.....II-111
Medical Diagnostic Laboratories Releases New Azithromycin Resistance Reflex Assay for
  Chlamydia Trachomatis.....II-111
BD Diagnostics Introduces New Molecular Test.....II-111
Nanosphere Receives FDA Authorization for Marketing BC-GP Test.....II-111
1$100
   Abbott Secures CE Marking for PLEX-ID™ System and Clinical Assays.....II-1121$100
   Thermo Fisher Scientific Acquires Life Technologies.....II-113
Myriad Genetics Takes Over Crescendo Bioscience.....II-113
AUT University Collaborates with Roche Diagnostics.....II-113
Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic
  Test Kit.....II-113
Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK.....II-113
B Braun US and CeGaT Join Forces to Establish B Braun CeGaT.....II-113
1$100
   Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and
  Autoantibody Technologies.....II-114
Veracyte and Fleury Partner to Offer the Afirma® Gene Expression Classifier.....II-114
Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood
  Test.....II-114
MDxHealth Enters into Agreement with Galaxy Health.....II-114
QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker.....II-114
1$100
   Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4™ POC CD4 Test.....II-115
Human Longevity Inc. Commences its Operations.....II-115
Roche Takes Over IQuum.....II-115
Myriad Genetics and Sividon Diagnostics Ink Exclusive Co-Marketing Agreement.....II-115
Grifols to Acquire Transfusion Diagnostics Unit of NOVARTIS Diagnostics.....II-115
Life Technologies and Advanced Cell Diagnostics Enter into Global Distribution
  Agreement.....II-115
1$100
   Microbiologics Acquires Phthisis Diagnostics.....II-116
bioMérieux Enters into Agreement to Acquire BioFire Diagnostics.....II-116
Response Genetics Takes Over Substantial Assets of Pathwork Diagnostics.....II-116
Mobidiag, Genewave and Amplidiag Merge.....II-116
EKF Diagnostics Holdings Established New Subsidiary.....II-116
Cynvenio and CollabRx Collaborate for Cancer Molecular Diagnostics.....II-116
bioTheranostics Inks Collaboration Agreement with Mayo Clinic and Mayo Medical
  Laboratories.....II-116
1$100
   bioMérieux Terminates Collaboration with Biocartis in Molecular Biology Field.....II-117
Rosetta Genomics Expands Distribution Agreement with GeneKor for microRNA Cancer
  Testing Services.....II-117
QIAGEN Enters into an Agreement with Eli Lilly.....II-117
Transgenomic Collaborates with PerkinElmer.....II-117
Diagnoplex and Unilabs Ink Collaboration Agreement to Commercialize Colox.....II-117
Pacific Edge Inks Agreement with FedMed.....II-117
PDI and Transgenomic Sign Long-Term Collaboration Agreement for CardioPredict™
  Molecular Diagnostic Test.....II-117
1$100
   HiberGene Obtains US Patent Rights for Molecular Diagnostic Test for
  Meningococcus.....II-118
OncoDNA Signs Collaboration Agreement with IBBL.....II-118
MDxHealth Collaborates with HistoGeneX.....II-118
Co-Diagnostics Partners with DNA Logix to Form Infectious Disease Dx Joint
  Venture.....II-118
Lumora and Promega Sign Supply Agreement for Ultra-Glo™ Luciferase.....II-118
MDxHealth Enters into Partnership with Summit Pharmaceuticals.....II-118
Myriad Genetic Enters into Agreement with TESARO.....II-118
1$100
   Cancer Genetics Enters into Distribution Agreement with Excilone.....II-119
Cancer Genetics Italia Enters into Agreement with Nikon Instruments.....II-119
CollabRx and OncoDNA Enter into Long-Agreement to Buy CollabRx SaaS-based Technology
  and Content Resources.....II-119
CollabRx Enters into Partnership with Sengenics for Molecular Diagnostics.....II-119
Diasorin Enters into Agreement with Seegene.....II-119
Cancer Genetics Appoints Cytogen and Cytogen Polska as Distributors for CGI Italia
  DNA-FISH Probes.....II-119
1$100
   FDA Re-Categorizes Meridian Bioscience’s illumigene® Group A Streptococcus and
  illumigene® Group B Streptococcus Tests.....II-120
Kreatech Signs Agreement with LCMC.....II-120
HiberGene Diagnostics Commences Manufacturing Process for Meningococcus MDx
  Test.....II-120
SYGNIS Pharma to Foray into Molecular Diagnostics Products Business.....II-120
IntelligentMDx Signs Long-Term Agreement with QIAGEN.....II-120
The Icahn School of Medicine Collaborates with Exosome Diagnostics.....II-120
Tianjin Cancer Hospital Joins Forces with Tektronix.....II-120
1$100
   Maverix Biomics Enters into Co-Marketing Agreement with QIAGEN.....II-121
CollabRx Enters into Multi-Year Agreement with Quest Diagnostics.....II-121
Personal Genome Diagnostics Collaborates with MolecularMD.....II-121
Applied Proteomics Collaborates with the German Cancer Research Center.....II-121
Diagnoplex and Unilabs Ink Collaboration Agreement.....II-121
CombiMatrix Enters into Strategic Alliance with Manhattan Labs.....II-121
MRIGlobal and Evogen Ink Agreement for Molecular Diagnostics Products
  Development.....II-121
1$100
   Rheonix Signs Joint Development Agreement with Life Technologies.....II-122
Qiagen Collaborates with Exosome Diagnostics.....II-122
Diaxonhit and XDx Sign Definitive Exclusive License and Distribution
  Agreement.....II-122
Genewiz Enters into Partnership with Chinese KeyTest Diagnostics.....II-122
IncellDx Inks Agreement with GeneCell Diagnostics.....II-122
PrimeraDx Enters into Agreement with Quest Diagnostics to Co-Develop Companion
  Diagnostics.....II-122
Evogen Inks Licensing Agreement with Focus Diagnostics.....II-122
1$100
   Lpath Enters into Collaboration and License Agreement with Provista.....II-123
Lab21 Inks Agreement with IntegraGen.....II-123
Analytik Jena Acquires SIRS-Lab.....II-123
Swift Biosciences Enters into Licensing Agreement with Vela Operations.....II-123
BioFire Secures $25 Million Fund from Athyrium.....II-123
1$100
   Abbott Laboratories (US).....II-124
Abbott Molecular, Inc. (US).....II-124
1$100
   Becton, Dickinson and Company (US).....II-125
bioMérieux SA (France).....II-125
1$100
   Cepheid (US).....II-1261$100
   CytoCore Inc. (US).....II-1271$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-1281$100
   GE Healthcare (US).....II-1291$100
   Grifols International, S.A. (Spain).....II-1301$100
   Hologic, Inc. (US).....II-1311$100
   Hologic Gen-Probe Incorporated (US).....II-132
QIAGEN N.V. (The Netherlands).....II-132
1$100
   Quest Diagnostics, Inc. (US).....II-1331$100
   Celera Corp. (US).....II-1341$100
   Siemens AG (Germany).....II-1351$100
   Tecan Group Ltd. (Switzerland).....II-136
The ELITechGroup SAS (France).....II-136
1$100
   Thermo Fisher Scientific (US).....II-1371$100
   Table 29: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-1381$350
   Table 30: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....II-1391$350
   Table 31: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-1401$350
   Molecular Diagnostics Market by Application.....II-141
Table 32: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-141
1$350
   Table 33: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....II-1421$350
   Table 34: World 15-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-1431$350
   Table 35: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-1441$350
   Table 36: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....II-1451$350
   Table 37: World 15-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-1461$350
   Table 38: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-1471$350
   Table 39: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....II-1481$350
   Table 40: World 15-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-1491$350
   Table 41: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-1501$350
   Table 42: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....II-1511$350
   Table 43: World 15-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....II-1521$350
   A. Market Analysis.....III-1
Molecular Diagnostics Maintain its Positive Momentum.....III-1
1$75
   A Glance at Major Growth Drivers.....III-21$75
   Key Challenges Facing the MDx Market.....III-3
qPCR and dPCR Instrumentation in the US: An Overview.....III-3
Ageing Demographics: Major Driving Factor.....III-3
1$75
   Table 44: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart).....III-41$200
   Table 45: US Population Breakdown by Age Group: 2012 (includes corresponding Graph/Chart).....III-5
Increasing Burden of Chronic Diseases Drives Focus onto Molecular
  Diagnostics.....III-5
US Individualized Medicine Market to Witness Significant Growth.....III-5
1$200
   Companion Diagnostic Market in the US.....III-61$75
   List of Select FDA-Cleared Companion Diagnostics.....III-7
Number of Companion Diagnostics under Development Keeps Soaring.....III-7
1$75
   Burgeoning Potential for Genetic Testing.....III-81$75
   Direct-to-Consumer Testing – A Growing Market.....III-9
Epidemic Proportion of Cancer in the US – Key Driver for Cancer Genetic
  Testing.....III-9
1$75
   Table 46: New Cancer Cases by Gender and Affected Site in the US (2013).....III-101$200
   Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing.....III-11
List of FDA-Cleared CF MDx Tests.....III-11
Table 47: CF Carrier Screening in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart).....III-11
1$200
   Table 48: CF Diagnostic Testing in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart).....III-12
Molecular Diagnostics Tests Gaining Share in STD Testing Domain.....III-12
HPV Testing Market – A Review.....III-12
1$200
   Table 49: Cervical Cancer by HPV Type in the US (2012): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart).....III-131$200
   Competitive Landscape.....III-14
Table 50: Leading Players in the US HPV Testing Market (2010 & 2011): Percentage Share Breakdown of Number of Tests for QIAGEN, Hologic, and Roche (includes corresponding Graph/Chart).....III-14
List of FDA Approved HPV MDx Tests.....III-14
1$200
   Regulatory Environment.....III-15
FDA Regulations.....III-15
Clinical Laboratory Improvement Amendments (CLIA).....III-15
2$150
   Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart).....III-17

Table 52: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart).....III-17
1$200
   Genetic Testing.....III-18
FDA to Implement Strict Measures for Cervical Cancer Screening Tests.....III-18
1$75
   Limited Reimbursements – A Major Hindrance.....III-19
New MoPath Codes for Reimbursement for Molecular Diagnostics Tests.....III-19
1$75
   Product Launches/Approvals.....III-208$495
   Strategic Corporate Developments.....III-287$495
   Key Players.....III-358$495
   B. Market Analytics.....III-43
Table 53: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-43
1$200
   Table 54: US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-441$200
   Table 55: US 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-451$200
   A. Market Analysis.....III-46
Current and Future Analysis.....III-46
1$75
   A Statistical Review of Cancer Incidence in Canada.....III-47
Table 56: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart).....III-47
1$200
   Table 57: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart).....III-481$200
   Product Approval.....III-49
B. Market Analytics.....III-49
Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-49
1$200
   Table 59: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-501$200
   Table 60: Canadian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-511$200
   A. Market Analysis.....III-52
Current and Future Analysis.....III-52
Demographics Drive Market Growth.....III-52
Table 61: Percentage Breakdown of Japanese Population by Age Group (2012) (includes corresponding Graph/Chart).....III-52
1$200
   Table 62: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart).....III-531$200
   B. Market Analytics.....III-54
Table 63: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-54
1$200
   Table 64: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-551$200
   Table 65: Japanese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-561$200
   A. Market Analysis.....III-57
Current and Future Analysis.....III-57
Debt Crisis in Europe Affects Healthcare Industry.....III-57
European Healthcare System: In a State of Transition?.....III-57
1$75
   Insight into Molecular Diagnostics Markets in Europe.....III-58 1$75
   Table 66: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart).....III-59
Increasing Testing Needs of the Elderly: Business Case for Molecular
  Diagnostics.....III-59
1$200
   Table 67: Population Breakup by Age Group for Select European Countries: 2012 (As a % of Total Population) (includes corresponding Graph/Chart).....III-601$200
   PCR Reagents in Europe: An Overview.....III-61
Automated Systems Gain Preeminence.....III-61
Oncology-based Molecular Diagnostics Holds Immense Potential.....III-61
1$75
   European Personalized Medicine Market to Exhibit Robust Growth.....III-621$75
   HPV Testing in Europe: An Overview.....III-63
List of Select CE-Marked HPV Molecular Diagnostic Tests.....III-63
1$75
   Table 68: Cervical Cancer Incidence and Mortality in European Countries (2012).....III-641$200
   Table 69: Prevalence of Cervical Cancer in European Countries (2012).....III-651$200
   Table 70: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart).....III-66
Regulatory Scenario in Europe for Companion Diagnostics.....III-66
Select European Players with Strong Biomarker Pipeline in Companion
  Diagnostics.....III-66
1$200
   Product Approvals/Launches.....III-671$75
   B. Market Analytics.....III-68
Table 71: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-68
1$200
   Table 72: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-691$200
   Table 73: European 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-701$200
   Table 74: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-711$200
   Table 75: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-721$200
   Table 76: European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-731$200
   A. Market Analysis.....III-74
Current and Future Analysis.....III-74
Product Launch.....III-74
Strategic Corporate Development.....III-74
Key Players.....III-74
2$150
   B. Market Analytics.....III-76
Table 77: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-76
1$200
   Table 78: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-771$200
   Table 79: French 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-781$200
   A. Market Analysis.....III-79
Current and Future Analysis.....III-79
Overview.....III-79
Strategic Corporate Developments.....III-79
1$75
   Siemens AG – A Key Player.....III-801$75
   B. Market Analytics.....III-81
Table 80: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-81
1$200
   Table 81: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-821$200
   Table 82: German 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-831$200
   A. Market Analysis.....III-84
Current and Future Analysis.....III-84
Product Launches.....III-84
1$75
   Strategic Corporate Developments.....III-85
B. Market Analytics.....III-85
Table 83: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-85
1$200
   Table 84: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-861$200
   Table 85: Italian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-871$200
   A. Market Analysis.....III-88
Current and Future Analysis.....III-88
SMIP for Pharmacogenomic Testing.....III-88
Product Launches.....III-88
1$75
   Strategic Corporate Developments.....III-891$75
   B. Market Analytics.....III-90
Table 86: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-90
1$200
   Table 87: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-911$200
   Table 88: The UK 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-921$200
   A. Market Analysis.....III-93
Current and Future Analysis.....III-93
Spain – Poised to become a Reckoning Force in Personalized Medicines.....III-93
Strategic Corporate Development.....III-93
1$75
   Grifols International, S.A. – A Key Player.....III-941$75
   B. Market Analytics.....III-95
Table 89: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-95
1$200
   Table 90: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-961$200
   Table 91: Spanish 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-971$200
   Market Analysis.....III-98
Table 92: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-98
1$200
   Table 93: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-991$200
   Table 94: Russian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1001$200
   A. Market Analysis.....III-101
Current and Future Analysis.....III-101
Product Launches/Approvals.....III-101
Strategic Corporate Developments.....III-101
3$225
   Key Players.....III-1044$300
   B. Market Analytics.....III-108
Table 95: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-108
1$200
   Table 96: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1091$200
   Table 97: Rest of European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1101$200
   A. Market Analysis.....III-111
Current and Future Analysis.....III-111
Healthcare Spending in Asia-Pacific: On the Rise.....III-111
In-vitro Diagnostics Market: India & China Offer Significant Growth
  Opportunities.....III-111
1$75
   Table 98: China and India Leads Global Population (July 2013): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart).....III-1121$200
   Table 99: Age-wise Breakup of China and India’s Population Vis-à-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart).....III-113
Molecular Diagnostics Testing Opens New World of Possibilities.....III-113
1$200
   Recent Advancements in Molecular Diagnostics Market: A Quick Review.....III-114
Novel Genetic Testing Methods.....III-114
Development of Personalized Healthcare Approaches.....III-114
1$75
   Molecular Painting for Genetic Diagnosis of Diseases.....III-115
New Technique to Detect H1N1 Virus.....III-115
Strategic Corporate Development.....III-115
1$75
   B. Market Analytics.....III-116
Table 100: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-116
1$200
   Table 101: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1171$200
   Table 102: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1181$200
   Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-1191$200
   Table 104: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1201$200
   Table 105: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1211$200
   A. Market Analysis.....III-122
Current and Future Analysis.....III-122
In-Vitro Diagnostics Market on the Growth Curve.....III-122
1$75
   HPV Testing in China: An Overview.....III-123
Government Support Drives Personalized Medicine Market in China.....III-123
Product Launches.....III-123
1$75
   Strategic Corporate Developments.....III-1241$75
   B. Market Analytics.....III-125
Table 106: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-125
1$200
   Table 107: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1261$200
   Table 108: Chinese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1271$200
   A. Market Analysis.....III-128
Current and Future Analysis.....III-128
A Focus on the Indian Molecular Diagnostics Market.....III-128
Molecular Diagnostic Market in India to Witness Significant Growth.....III-128
1$75
   Growth Drivers in a Nut Shell.....III-129
Growing Investments in Pharmacogenomics Research Drives Personalized
  Medicine.....III-129
1$75
   Indian Scientific Research towards Functional Genomics and Proteomics.....III-1301$75
   Automation – The Emerging Trend in IVD Industry.....III-131
Growing Investments in Pharmacogenomics Research Drives Personalized
  Medicine.....III-131
1$75
   HPV Testing Market: An Overview.....III-132 1$75
   Table 109: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart).....III-133
Product Launches/Approvals.....III-133
1$200
   B. Market Analytics.....III-134
Table 110: Rest of Asia Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-134
1$200
   Table 111: Rest of Asia Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1351$200
   Table 112: Rest of Asia Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1361$200
   A. Market Analysis.....III-137
Current and Future Analysis.....III-137
Brazilian IVD Market on the Rise.....III-137
1$75
   B. Market Analytics.....III-138
Table 113: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-138
1$200
   Table 114: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1391$200
   Table 115: Latin American 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1401$200
   A. Market Analysis.....III-141
Current and Future Analysis.....III-141
Product Launch.....III-141
1$75
   B. Market Analytics.....III-142
Table 116: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart).....III-142
1$200
   Table 117: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart).....III-1431$200
   Table 118: Rest of World 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart).....III-1441$200
  
Total Companies Profiled: 165 (including Divisions/Subsidiaries - 179)

Region/Country Players

The United States 113 Canada 3 Japan 1 Europe 50 France 7 Germany 11 The United Kingdom 12 Italy 2 Spain 1 Rest of Europe 17 Asia-Pacific (Excluding Japan) 11 Middle East 1
Click here to request a full table of contents and more details on this project.